K-numberK251031
Device nameFiber Laser Treatment Systems (HS-232,HS-233)
ApplicantShanghai Apolo Medical Technology Co., Ltd.
Product codeONG
Device classClass II
Decision dateJul 2, 2025
DecisionSubstantially Equivalent
Regulation878.4810
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Fiber Laser Treatment Systems (HS-232 desktop and HS-233 mobile models) are Erbium (1550nm) and Thulium (1927nm) fiber lasers for dermatological procedures. The 1550nm wavelength is used for fractional skin resurfacing and soft tissue coagulation, while the 1927nm wavelength is used for soft tissue coagulation only. The system includes a mainframe with touch-screen controls, power supply, cooling system, fiber handpiece, and footswitch activation.

Technological characteristics

Both 1550nm and 1927nm lasers operate independently with selectable output sources. The 1550nm laser specifications (frequency, energy, pulse width) are similar to predicates and meet the same safety/EMC/performance standards. The 1927nm laser has a 15W output power (higher than predicate but within acceptable range) and lower minimum pulse energy that does not create new safety concerns. Both use identical handpiece tips to the predicate device K221770. The aiming beam (650nm, <2mW) and treatment area are comparable to predicates.

Test standards cited

IEC 60601-1:2005+A1:2012+A2:2020 (medical electrical equipment general safety); IEC 60601-1-2:2014+A1:2020 (electromagnetic compatibility); IEC 60601-2-22:2019 (surgical/cosmetic/therapeutic/diagnostic laser equipment); IEC 60825-1:2014 (laser product safety and classification).

Substantial equivalence argument

For the 1550nm indication, the proposed device uses identical technology, specifications, and patient-contact materials (handpiece tips) as the predicate K221770, achieving the same intended use with equivalent safety profiles. For the 1927nm indication covered by predicate K130193, although output power differs slightly (15W vs. predicate range), the minor difference does not affect safety or effectiveness. The lower minimum pulse energy does not introduce new safety issues. Identical handpiece design and comparable aiming beam/treatment area parameters across both wavelengths ensure substantial equivalence despite these minor technical variations.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →